<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581280</url>
  </required_header>
  <id_info>
    <org_study_id>4-2014-0919</org_study_id>
    <nct_id>NCT02581280</nct_id>
  </id_info>
  <brief_title>Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Remifentanil, Sufentanil, Clopidogrel, Ticagrelor During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)</brief_title>
  <official_title>Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Remifentanil, Sufentanil, Clopidogrel, Ticagrelor During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extracorporeal membrane oxygenation (ECMO) is the device which increases the supply of oxygen
      to the body tissues in vitro and to assist in heart and lung function. Venoarterial (VA) ECMO
      is used in patients with cardiogenic shock, cardiac arrest, ventricular arrhythmia and is
      able to secure a time to self-recovery by reducing the excessive stimulation applied to the
      heart. However, in ECMO patients, pharmacokinetics of drugs are changing such as increased
      volume of distribution (Vd) or decreased clearance (CL). For this reason, it is hard to
      provide the best treatment in ECMO patients. The study is to evaluate whether the PK of drugs
      is influenced by VA ECMO and to recommend the optimal dosing strategies for proposed drugs in
      adult patients receiving VA ECMO.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum or plasma concentration</measure>
    <time_frame>Between day0 to day3 after removing ECMO</time_frame>
    <description>Serum or plasma concentration of teicoplanin or levofloxacin or piperacillin/tazobactam or remifentanil or sufentanil or clopidogrel or ticagrelor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Cmax</measure>
    <time_frame>Between day0 to day3 after removing ECMO</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Tmax</measure>
    <time_frame>Between day0 to day3 after removing ECMO</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance</measure>
    <time_frame>Between day0 to day3 after removing ECMO</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>volume of distribution</measure>
    <time_frame>Between day0 to day3 after removing ECMO</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>absorption rate constant</measure>
    <time_frame>Between day0 to day3 after removing ECMO</time_frame>
    <description>absorption rate constant (if the drug is orally administered),</description>
  </primary_outcome>
  <primary_outcome>
    <measure>elimination half life</measure>
    <time_frame>Between day0 to day3 after removing ECMO</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the curve (AUC)</measure>
    <time_frame>Between day0 to day3 after removing ECMO</time_frame>
    <description>area under the curve (AUC) (if possible)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Cardiac Dysfunction</condition>
  <arm_group>
    <arm_group_label>On ECMO</arm_group_label>
    <description>patients who are concomitantly receiving teicoplanin or levofloxacin or piperacillin/tazobactam or remifentanil or sufentanil or clopidogrel or ticagrelor during ECMO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Off ECMO</arm_group_label>
    <description>patients who are concomitantly receiving teicoplanin or levofloxacin or piperacillin/tazobactam or remifentanil or sufentanil or clopidogrel or ticagrelor after removing ECMO</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Residual blood</intervention_name>
    <description>Residual blood samples(1~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).</description>
    <arm_group_label>On ECMO</arm_group_label>
    <arm_group_label>Off ECMO</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Residual blood samples(1~2 cc) at each sampling time are collected from all subjects while
      using ECMO for drug concentration assays(LC-MS/MS etc.). After ECMO device is removed,
      residual arterial blood samples(1~2 mls) at each sampling time are collected and drug
      concentrations are assayed.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients over the age of 19 who are receiving teicoplanin or levofloxacin or
        piperacillin/tazobactam or remifentanil or sufentanil or clopidogrel or ticagrelor while
        using VA ECMO in Severance Hospital, Yonsei University Health System.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient who are â‰¥ 19 years old and receiving VA ECMO in Severance Hospital, Yonsei
             University Health System.

          -  patient who are receiving one of these drugs: teicoplanin or levofloxacin or
             piperacillin/tazobactam or remifentanil or sufentanil or clopidogrel or ticagrelor

          -  patients who are agreed to participate in this study

        Exclusion Criteria:

          -  patients who are pregnant

          -  patients who are receiving drugs that could affect study drug's concentration due to
             drug-drug interaction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Wi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin Wi, MD</last_name>
    <phone>82-2-2228-8460</phone>
    <email>caesar@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Wi, MD</last_name>
      <phone>82-2-2228-8460</phone>
      <email>caesar@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2015</study_first_submitted>
  <study_first_submitted_qc>October 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>December 9, 2015</last_update_submitted>
  <last_update_submitted_qc>December 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Teicoplanin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

